8.1K
Articles
237.5K
Citations
3.1
avg. Impact Factor
199
h-index

Most Cited Articles of Division of Hematology in 2008

TitleJournalYearCitations
Improved survival in multiple myeloma and the impact of novel therapiesBlood20081.8K
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia2008780
von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)Haemophilia2008676
Multiple myelomaBlood2008654
The epidemiology of venous thromboembolism in the communityArteriosclerosis, Thrombosis, and Vascular Biology2008511
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJournal of Clinical Oncology2008424
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and TreatmentLeukemia2008355
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical TrialsMayo Clinic Proceedings2008283
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myelomaJournal of Clinical Oncology2008278
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaBlood2008254
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisalLeukemia2008239
Genetic aberrations and survival in plasma cell leukemiaLeukemia2008236
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survivalLeukemia2008229
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741Journal of Clinical Oncology2008229
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trialsLeukemia2008185
Clinically relevant end points and new drug approvals for myelomaLeukemia2008156
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupBlood2008153
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chainsKidney International2008140
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myelomaJournal of Clinical Oncology2008139
Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trialsMayo Clinic Proceedings2008138
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemLeukemia2008120
Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomasLeukemia2008118
Host genetic variation contributes to phenotypic diversity in myeloproliferative disordersBlood2008115
Risk factors for leukemic transformation in patients with primary myelofibrosisCancer2008112
Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysisAmerican Journal of Hematology2008110